Nevertheless, our total sample of the primary tumors did not demonstrate it, most likely because the half of them were the lobular carcinomas in which the HER2/neu is rarely expressed [47, 77–79], nor the IDC, probably because of the weaker HER2/neu expression in the invasive carcinomas than in in situ carcinomas [49]. This evidence concerns the gene ERBB2 and in situ carcinoma.